In this regard, CAR T cells engineered to secrete PD-1/PD-L1 antagonists [209,210,211], to be deficient in PD-1 expression [212,213], to bispecifically target other B-cell markers (such as CD20 or CD22) in addition to CD19 [214,215], or to be administered in combination with immune-checkpoint inhibitors [216,217] are promising alternatives in the treatment of DLBCL. Here, CD22 is linked to diffuse large B-cell lymphoma.